CD274 and hereditary sensory and autonomic neuropathy: In previously published clinical trials, the incidence of CIP was about 3–5% [6, 7, 14–16], which mostly are CIP G2-3 with the incidence of G4 being only 0.67% [17].The incidence of CIP of PD-L1 inhibitor was lower than that of PD-1 inhibitor.